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/e combination of artemether/lumefantrine is indicated for the treatment of acute uncomplicated Plasmodium falciparum
malaria. /ere have been no clinical trials to assess the efficacy of this medication in patients with renal impairment. While it is
unlikely that artemether/lumefantrine would be removed during dialysis, clinical experience regarding drug use in this setting is
limited. In this article, the authors report successful treatment of Plasmodiummalariaemalaria on a patient with end-stage kidney
disease undergoing hemodialysis.
1. Introduction
/e combination of artemether/lumefantrine is indicated for
the treatment of acute uncomplicated Plasmodium falciparum
malaria [1, 2]. No clinical trials have been conducted in
patients with renal impairment, although no significant renal
excretion of its components was reported in healthy volun-
teers [3]. Moreover, no data exist on these drugs dialyzability
but physicochemical characteristics of artemether/
lumefantrine suggest that significant drug removal is un-
likely during dialysis [4]. Clinical experience is limited and, to
our knowledge, few cases have been published reporting its
use in patients with acute kidney disease [5].
Despite no data provided by themanufacturers about the
effectiveness of artemether/lumefantrine against Plasmo-
dium malariae, a study performed in Central Africa showed
high rates of cure of nonfalciparum malaria with this
combination [6] and current guidelines recommend the
treatment of uncomplicated P. malariae malaria with an
artemisinin-based combination therapy [1].
2. Case Presentation
We describe a clinical case of a 56-year-old woman from
Angola, with diabetic end-stage kidney disease under
maintenance hemodialysis and chronic anemia with frequent
blood transfusion requirements, who presented with lumbar
back pain and lower extremity muscle weakness for 3 months.
/e patient reported myalgia, rigors, and epigastric pain for 1
month, which had worsened in the previous 7 days, at which
time she travelled to Portugal. At presentation, the patient’s vital
signs were normal, and physical examination was remarkable
for pallor and proximal weakness of the lower limbs. Blood tests
on admission revealed anemia (hemoglobin 6g/dL, mean
corpuscular volume 67.1 fL, mean corpuscular hemoglobin
concentration 20.5pg, hematocrit 19.6%, and red cell distri-
bution width 28%), leukocyte count 8.6×109/L and platelet
count 77×109/L, C-reactive protein 26.88mg/dL, creatinine
8.36mg/dL, and urea 141mg/dL, with no evidence of hemolysis.
/e peripheral blood smear revealed trophozoites and schizonts
of Plasmodium malariae, and the patient was treated with
artemether/lumefantrine for 3 days, under cardiac monitoring
with electrocardiogram and blood potassium monitoring. No
infected erythrocytes were identified on peripheral blood smear
after treatment conclusion, and no adverse eventswere reported.
3. Discussion
In conclusion, artemether/lumefantrine may be safe for
patients with end-stage kidney failure. Nevertheless, studies
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on end-stage kidney disease patients are warranted to
support its safe and efficacious use. Close monitoring of
these patients with a multidisciplinary team is essential.
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